Ladenburg Thalmann Downgrades CONMED (CNMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Conmed (CNMD) Misses Q1 EPS by 2c, Offers FY15 Guidance
April 22, 2015 4:52 PM EDTConmed (NASDAQ: CNMD) reported Q1 EPS of $0.42, $0.02 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $177.9 million versus the consensus estimate of $176.16 million.
Conmed sees FY2015 EPS of $1.82-$1.92, versus the consensus of $1.86. Conmed sees FY2015 revenue of $723-738... More
